Palantir Technologies Inc. is trading 4.2% down at $145.82 following critical scrutiny from UK lawmakers regarding its major health-data contract with the NHS.
- Members of the UK Parliament’s Science, Innovation and Technology Committee labeled the NHS reliance on the firm an unacceptable point of weakness, raising concerns over digital sovereignty and vendor lock-in.
- The negative governance and regulatory spotlight is pressuring investor sentiment despite only modest declines in the broader U.S. indices.